GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » EV-to-EBITDA

Syncom Formulation (India) (NSE:SYNCOMF) EV-to-EBITDA : 28.68 (As of May. 11, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Syncom Formulation (India)'s enterprise value is ₹12,454 Mil. Syncom Formulation (India)'s EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹434 Mil. Therefore, Syncom Formulation (India)'s EV-to-EBITDA for today is 28.68.

The historical rank and industry rank for Syncom Formulation (India)'s EV-to-EBITDA or its related term are showing as below:

NSE:SYNCOMF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.35   Med: 11.95   Max: 51.28
Current: 28.66

During the past 13 years, the highest EV-to-EBITDA of Syncom Formulation (India) was 51.28. The lowest was 2.35. And the median was 11.95.

NSE:SYNCOMF's EV-to-EBITDA is ranked worse than
79.8% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.76 vs NSE:SYNCOMF: 28.66

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Syncom Formulation (India)'s stock price is ₹13.05. Syncom Formulation (India)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹0.340. Therefore, Syncom Formulation (India)'s PE Ratio for today is 38.38.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Syncom Formulation (India) EV-to-EBITDA Historical Data

The historical data trend for Syncom Formulation (India)'s EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syncom Formulation (India) EV-to-EBITDA Chart

Syncom Formulation (India) Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.04 2.28 5.19 29.24 16.53

Syncom Formulation (India) Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.23 16.53 19.70 20.48 32.55

Competitive Comparison of Syncom Formulation (India)'s EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syncom Formulation (India)'s EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s EV-to-EBITDA falls into.



Syncom Formulation (India) EV-to-EBITDA Calculation

Syncom Formulation (India)'s EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=12454.009/434.294
=28.68

Syncom Formulation (India)'s current Enterprise Value is ₹12,454 Mil.
Syncom Formulation (India)'s EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹434 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syncom Formulation (India)  (NSE:SYNCOMF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Syncom Formulation (India)'s PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.05/0.340
=38.38

Syncom Formulation (India)'s share price for today is ₹13.05.
Syncom Formulation (India)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.340.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Syncom Formulation (India) EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Traded in Other Exchanges
Address
207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines